Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simeprevir + sofosbuvir
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination of simeprevir (an HCV NS3/4A protease inhibitor) and sofosbuvir (a nucleotide analog NS5B polymerase inhibitor) used as an all-oral regimen for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. This interferon-free combination therapy was one of the first all-oral regimens used in clinical practice to treat HCV infection, demonstrating high sustained virologic response rates.
- Brand names
- Olysio + Sovaldi
- Other names
- sofosbuvir + simeprevir
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on simeprevir + sofosbuvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simeprevir + sofosbuvir.